Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading MTVA daily closes…
Loading price history…
Pipeline assets
DA-1726
Phase 1 · Active
Target GLP1R / GCGR
Partnerships Dong-A ST (related party; exclusive global license ex-Korea under 2022 License Agreement)
Indications
obesity(Stage not disclosed)
metabolic dysfunction-associated steatohepatitis (potential)(Stage not disclosed)
Catalysts
— None
Status note First-in-human Phase 1 trial initiated 2024; Parts 3a/3b titration studies started April 2026 with dose titration completed July 2026. Dose titration studies designed to improve tolerability and enable higher dose levels.
vanoglipel
Phase 2 · Active
Aliases DA-1241
Target GPR119
Partnerships Dong-A ST (related party; exclusive global license ex-Korea under 2022 License Agreement; may also develop for type 2 diabetes)
Indications
metabolic dysfunction-associated steatohepatitis (MASH)(Stage not disclosed)
Catalysts
— None
Status note Phase 2a first-in-human MASH trial initiated 2023. Company expects to discuss development pathway for a vanoglipel combination therapy.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.